PMID- 17658969
OWN - NLM
STAT- MEDLINE
DCOM- 20070831
LR  - 20191110
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 22
IP  - 3
DP  - 2007 Mar
TI  - The safety of intravenous iron sucrose use in the elderly patient.
PG  - 230-8
AB  - BACKGROUND: This study was undertaken to assess the safety and tolerability of 
      the use of intravenous (IV) iron sucrose in the therapy of iron-deficiency anemia 
      in elderly, hemodialysis dependent (HDD), chronic kidney disease (CKD) patients. 
      METHODS: This was a multicenter, open-label study in a large consecutive sample 
      of 665 HDD-CKD patients (in 11 locations). Patients received IV iron sucrose 
      therapy in treatment and maintenance dosing cycles over 10-week periods. There 
      were 10 doses of 100 mg of iron sucrose in each drug cycle, and participants 
      could receive multiple cycles of either or both regimens. Variables evaluated in 
      the intent-to-treat population included adverse events (AEs), hemoglobin, and 
      iron indices. RESULTS: Of the 665 patients, 391 patients were under the age of 65 
      (younger adults) and 274 were 65 years of age or older (elder adults). Iron needs 
      and erythropoietin dosing were similar in both the elder and younger adult 
      patients. The incidence, severity, and nature of AEs and overall mortality were 
      similar in both age groups. There were no drug-related deaths or drug-related 
      serious AEs in either group. There were no hypersensitivity reactions or allergic 
      reactions in either patient population, even among those with a prior history of 
      intolerance to other parenteral-iron products. Comparison of the two age groups 
      also revealed no differences in the efficacy of iron treatment as reflected by 
      hemoglobin, transferring saturation, and ferritin response. CONCLUSIONS: There is 
      no apparent difference in the safety and efficacy of iron sucrose between elder 
      and younger adults in the treatment of iron-deficiency anemia in HDD patients 
      with CKD.
FAU - Reed, John
AU  - Reed J
AD  - Fresenius Medical Care-North America, Clinics of Southeast, Columbus, Mississippi 
      39705, USA. drreed03@cableone.net
FAU - Charytan, Chaim
AU  - Charytan C
FAU - Yee, Jerry
AU  - Yee J
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Ferric Compounds)
RN  - 0 (Hematinics)
RN  - 11096-26-7 (Erythropoietin)
RN  - FZ7NYF5N8L (Ferric Oxide, Saccharated)
RN  - QLZ991V4A2 (Glucaric Acid)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia, Iron-Deficiency/drug therapy/etiology
MH  - Erythropoietin/therapeutic use
MH  - Female
MH  - Ferric Compounds/administration & dosage/*adverse effects/therapeutic use
MH  - Ferric Oxide, Saccharated
MH  - Geriatrics
MH  - Glucaric Acid
MH  - Hematinics/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Kidney Failure, Chronic/complications
MH  - Male
MH  - Middle Aged
MH  - Renal Dialysis
EDAT- 2007/07/31 09:00
MHDA- 2007/09/01 09:00
CRDT- 2007/07/31 09:00
PHST- 2007/07/31 09:00 [pubmed]
PHST- 2007/09/01 09:00 [medline]
PHST- 2007/07/31 09:00 [entrez]
AID - 10.4140/tcp.n.2007.230 [doi]
PST - ppublish
SO  - Consult Pharm. 2007 Mar;22(3):230-8. doi: 10.4140/tcp.n.2007.230.